<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960880</url>
  </required_header>
  <id_info>
    <org_study_id>18735</org_study_id>
    <nct_id>NCT02960880</nct_id>
  </id_info>
  <brief_title>Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists</brief_title>
  <official_title>Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the real world comparative effectiveness of Rivaroxaban
      prescribed in non-valvular atrial fibrillation (NVAF) routine care patients in Germany.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2016</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">December 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Risk of ischemic stroke estimated as the number of hospitalizations with the ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk of intracranial hemorrhage (ICH) estimated as the number of hospitalizations with the ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk of ischemic stroke or ICH estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of systemic embolism (SE) estimated as the number of hospitalizations with the ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of transient ischemic attack (TIA) estimated as the number of hospitalizations with the ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of ischemic stroke or SE or TIA estimated as the number of hospitalizations with the respective ICD-10-GM diagnosis</measure>
    <time_frame>Within time of drug exposure (Retrospective period of 5 years and 3 months)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">99999</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <description>NVAF patients who were newly initiated on Rivaroxaban for stroke prevention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phenprocoumon</arm_group_label>
    <description>NVAF patients who were newly initiated on Phenprocoumon for stroke prevention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban (Xarelto, BAY597939)</intervention_name>
    <description>15mg, 20mg</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenprocoumon (branded and generics)</intervention_name>
    <description>Individually adjusted dose</description>
    <arm_group_label>Phenprocoumon</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly initiated with Rivaroxaban or Phenprocoumon with an NVAF diagnosis from
        January 1, 2012 through December 31, 2015. Patients will be identified from the HRI
        research database, a complete longitudinal dataset of patients under statutory health
        insurance in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First dispense date of Rivaroxaban (15mg or 20mg - PZN based) or Phenprocoumon (PZN
             based) between January 1, 2012 and December 31, 2015

          -  At least two verified outpatient diagnoses or one inpatient diagnosis (main or
             secondary diagnosis) of NVAF (ICD-10 GM I48.0/I48.1/I48.2/I48.9) in the individual
             time frame of 4 quarters before the index date (pre-index period) or within the index
             quarter

          -  Patients will be required to have 4 quarters of enrollment for the assessment of
             baseline characteristics and be observable and insured in the database for at least
             one day after their individual index date (post-index period)

          -  â‰¥ 18 years of age

        Exclusion Criteria:

          -  Patients with valvular AF [4 quarters prior to the index date]

          -  Pregnancy [4 quarters prior to index date]

          -  Malignant cancers [4 quarters prior to the index date or &quot;condition after&quot;]

          -  Transient cause of AF [4 quarters prior to index date]

          -  Patients with VTE (pulmonary embolism or DVT) [60 days before index]

          -  Patients with major surgery defined as hip or knee replacement [60 days before index]

          -  Prescriptions of OACs (Rivaroxaban, VKA, Dabigatran, Apixaban) before index date [4
             quarters prior to index date]

          -  Patients receiving more than one anticoagulant substance (Apixaban, Dabigatran,
             Rivaroxaban or Phenprocoumon) or more than one dosage of a substance on the index date

          -  For sensitivity analysis : Patient with any of the events defined in the combined
             endpoints [4 quarters prior to index date or &quot;condition after&quot;

          -  Patients with dialysis [4 quarters prior to index date]
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban, Phenprocoumon, retrospective cohort study, Non-Valvular Atrial fibrillation, NVAF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

